Osteoporosis constitutes a major public health concern. The economic burden of osteoporotic fractures in EU is expected to increase 25% by 2025 compared to 2010. These estimates may indicate an inefficiency of current drugs for osteoporosis. Actually, the use of pharmacological agents for osteoporosis has been decreasing in EU, probably due to the reported side effects. Therefore, there is a need for innovative agents to reduce the burden of osteoporosis. The COLOSTEO project will build on the complementary expertise of research and industrial partners through knowledge sharing between sectors.

 News

The COLOSTEO project came to an end, after 4 years of exploring the creation of an innovative nutraceutical product based on colostrum to prevent osteoporosis! Our findings and the conclusion of our research studies will stay available to all.

RISK FACTORS OF OSTEOPOROSIS_001.png
MYTHS OF OSTEPOROSIS_001.png